View Post

Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206

In Clinical Trials by Barbara Jacoby

Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for ONC206, allowing the first-in-human trial of the compound. ONC206 is the first of the family of drug candidates, which we call “imipridones”, that possess the same core chemical structure as ONC201. The first clinical trial for ONC206 in adults …